课题基金 / 基金详情

Hormone therapy induces reprogramming to drive aggressive prostate cancer

Hormone therapy induces reprogramming to drive aggressive prostate cancer
激素疗法诱导重编程以驱动侵袭性前列腺癌
批准号:
380656
负责人:
Zoubeidi Amina
金额:
$48.76万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2018
资助国家:
加拿大
项目状态:
已结题
起止时间:
2018-03-01 至 2023-03-01
关键词:

项目摘要

项目成果

Zoubeidi Amina的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Targeting the androgen receptor (AR) has been the cornerstone of treatment for men suffering from prostate cancer, essentially starving tumors of the fuel they need to grow and survive. However, these therapies have been a double-edged sword; undoubtedly
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Canada Research Chairs - Tier 1
  • 批准号:
    441804
  • 项目类别:
  • 资助金额:
    $101.99万
  • 财政年份:
    2020
  • 负责人:
    Zoubeidi Amina
  • 依托单位:
The role of the lineage oncogene ASCL1 in treatment-induced neuroendocrine prostate cancer
  • 批准号:
    409458
  • 项目类别:
    Operating Grants
  • 资助金额:
    $61.3万
  • 财政年份:
    2019
  • 负责人:
    Zoubeidi Amina
  • 依托单位:
海外基金